TMBR

Timber Pharmaceuticals, Inc. (TMBR) | Rumor.io

Timber Pharmaceuticals

TMBR

Attention (50-day avg)0%

Attention rank (50-day avg)—

Bullish sentiment (50-day avg)—

Price to earnings ratio0

Market capitalization0

Earnings per share0

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)0

Social

What share of all stock conversation is about TMBR?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% +0

Nov 29

$TMBR's common stock was halted on Nov 29, 2023, due to NYSE American delisting proceedings.
Timber Pharmaceuticals announced commencement of delisting proceedings, with common stock expected to begin trading on the OTC market.
Trading in $TMBR resumed on Nov 29, 2023, after the company received court approval of all "first day" motions to support business operations.

Generated by AI

Sentiment

Of the messages about TMBR that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	100%
Bearish	—	—	—	0%

Bullish· Jun 5

$TMBR is showing strength with 13.5% gain until now, with the potential for further growth.
The company has made a positive decision from the FDA for its TMB-001 treatment, indicating a promising development for the biotech stock.
Timber Pharmaceuticals, Inc. has been a big winner for some investors, with one user making a cool overnight gain and another user banking hard on the stock.

Bearish· Mar 11

The short interest in $TMBR has increased significantly, with short volume reaching over 50% of total volume, and the short float at 36% of the float, which could lead to a short squeeze.
$TMBR has a low float and is heavily shorted, making it vulnerable to a sharp price increase if short sellers are forced to cover their positions.
There has been a large dump of $TMBR shares near the closing bell, which could be a sign of shorts playing Russian roulette and potentially leading to a short squeeze.

Generated by AI

Topics

Of the messages about TMBR that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	—	—	0%
Announcements	—	—	—	96.72%
Controversies	—	—	—	0%
Earnings	—	—	—	0%
Macro	—	—	—	0%
Technical Analysis	—	—	—	3.28%

Announcements· Aug 21

Timber Pharmaceuticals, Inc. ($TMBR) has agreed to be acquired by LEO Pharma in a deal worth up to $36 million, with an initial upfront consideration of $14 million and up to an additional $22 million in contingent value rights.
The acquisition provides Timber stockholders with upfront cash consideration and downstream value through contingent value rights, with the potential for up to $22 million in additional payments.
The transaction is expected to close by the end of the deal, with Timber stockholders set to receive a total of up to $6.73 per share, including the upfront cash and contingent value rights.

Technical Analysis· Mar 17

$TMBR broke downtrend, with a potential pullback and new highs coming.
A longer-term reversal is looking more promising, with a great close on the 4H chart.
Key levels to watch are 1.95 support and 2.65 resistance, with a potential move to 3 if 2.65 is broken.

Generated by AI

Community

Of the messages about TMBR, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	—	1.39%
Newcomers	—	—	—	98.61%

Regulars· Aug 21

$TMBR has been acquired by LEO Pharma in a deal worth up to $36 million, with an expected close by and contingent value rights worth up to $22 million.
The acquisition has led to a significant increase in $TMBR's stock price, with a 110% gain in premarket trading and a 100% increase in the last day.
The deal provides $TMBR stockholders with upfront cash consideration and downstream value through contingent value rights, with the potential for a $14 million upfront payment or a payment of $2.62 per share.

Newcomers· Aug 21

$TMBR is being acquired by LEO Pharma for up to $36M, with an initial upfront consideration of $14M and up to an additional $22M in contingent value rights.
Newcomers are focusing on the potential for a deep fade in $TMBR, with some expecting a drop to at least $2.5 and others anticipating a move towards $2.
Some users are looking to short $TMBR against the pre-market high based on the acquisition news, with others recognizing consolidation and covering their positions.

Generated by AI

Also Discussed

Investors talking about TMBR also mention

#	Name	Attention
1	GLG - TD Holdings, Inc.	——
2	CSCW - Color Star Technology Co., Ltd.	——
3	CBAK Energy Technology LimitedCBAT	0%0
4	Corbus Pharmaceuticals Holdings, Inc.CRBP	0%0
5	MDGS - Xylo Technologies Ltd.	——
6	KIQ - Kelso Technologies Inc.	——
7	Iterum Therapeutics plcITRM	0%0
8	China SXT Pharmaceuticals, Inc.SXTC	0%0
9	Onconova Therapeutics IncONTX	0%0
10	THMO - ThermoGenesis Holdings, Inc.	——